COVID-19 in children treated with immunosuppressive medication for kidney diseases.
nephrology
virology
Journal
Archives of disease in childhood
ISSN: 1468-2044
Titre abrégé: Arch Dis Child
Pays: England
ID NLM: 0372434
Informations de publication
Date de publication:
21 Dec 2020
21 Dec 2020
Historique:
received:
03
09
2020
revised:
06
11
2020
accepted:
16
11
2020
entrez:
23
12
2020
pubmed:
24
12
2020
medline:
24
12
2020
Statut:
aheadofprint
Résumé
Children are recognised as at lower risk of severe COVID-19 compared with adults, but the impact of immunosuppression is yet to be determined. This study aims to describe the clinical course of COVID-19 in children with kidney disease taking immunosuppressive medication and to assess disease severity. Cross-sectional study hosted by the European Rare Kidney Disease Reference Network and supported by the European, Asian and International paediatric nephrology societies. Anonymised data were submitted online for any child (age <20 years) with COVID-19 taking immunosuppressive medication for a kidney condition. Study recruited for 16 weeks from 15 March 2020 to 05 July 2020. The primary outcome was severity of COVID-19. 113 children were reported in this study from 30 different countries. Median age: 13 years (49% male). Main underlying reasons for immunosuppressive therapy: kidney transplant (47%), nephrotic syndrome (27%), systemic lupus erythematosus (10%). Immunosuppressive medications used include: glucocorticoids (76%), mycophenolate mofetil (MMF) (54%), tacrolimus/ciclosporine A (58%), rituximab/ofatumumab (11%). 78% required no respiratory support during COVID-19 illness, 5% required bi-level positive airway pressure or ventilation. Four children died; all deaths reported were from low-income countries with associated comorbidities. There was no significant difference in severity of COVID-19 based on gender, dialysis status, underlying kidney condition, and type or number of immunosuppressive medications. This global study shows most children with a kidney disease taking immunosuppressive medication have mild disease with SARS-CoV-2 infection. We therefore suggest that children on immunosuppressive therapy should not be more strictly isolated than children who are not on immunosuppressive therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Children are recognised as at lower risk of severe COVID-19 compared with adults, but the impact of immunosuppression is yet to be determined. This study aims to describe the clinical course of COVID-19 in children with kidney disease taking immunosuppressive medication and to assess disease severity.
METHODS
METHODS
Cross-sectional study hosted by the European Rare Kidney Disease Reference Network and supported by the European, Asian and International paediatric nephrology societies. Anonymised data were submitted online for any child (age <20 years) with COVID-19 taking immunosuppressive medication for a kidney condition. Study recruited for 16 weeks from 15 March 2020 to 05 July 2020. The primary outcome was severity of COVID-19.
RESULTS
RESULTS
113 children were reported in this study from 30 different countries. Median age: 13 years (49% male). Main underlying reasons for immunosuppressive therapy: kidney transplant (47%), nephrotic syndrome (27%), systemic lupus erythematosus (10%). Immunosuppressive medications used include: glucocorticoids (76%), mycophenolate mofetil (MMF) (54%), tacrolimus/ciclosporine A (58%), rituximab/ofatumumab (11%). 78% required no respiratory support during COVID-19 illness, 5% required bi-level positive airway pressure or ventilation. Four children died; all deaths reported were from low-income countries with associated comorbidities. There was no significant difference in severity of COVID-19 based on gender, dialysis status, underlying kidney condition, and type or number of immunosuppressive medications.
CONCLUSIONS
CONCLUSIONS
This global study shows most children with a kidney disease taking immunosuppressive medication have mild disease with SARS-CoV-2 infection. We therefore suggest that children on immunosuppressive therapy should not be more strictly isolated than children who are not on immunosuppressive therapy.
Identifiants
pubmed: 33355203
pii: archdischild-2020-320616
doi: 10.1136/archdischild-2020-320616
pmc: PMC7754669
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : CommentIn
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Am J Transplant. 2020 Jul;20(7):1849-1858
pubmed: 32301155
J Card Fail. 2020 Jun;26(6):457-461
pubmed: 32417380
Lancet Child Adolesc Health. 2020 May;4(5):e10-e11
pubmed: 32278365
Pediatrics. 2020 Jun;145(6):
pubmed: 32179660
Kidney Int. 2020 Dec;98(6):1540-1548
pubmed: 32979369
JAMA Pediatr. 2021 Feb 1;175(2):143-156
pubmed: 32975552
J Pediatr Gastroenterol Nutr. 2020 Jun;70(6):727-733
pubmed: 32443020
N Engl J Med. 2020 Jul 23;383(4):347-358
pubmed: 32598830
Lancet Child Adolesc Health. 2020 Sep;4(9):653-661
pubmed: 32593339
Am J Transplant. 2020 Jul;20(7):1800-1808
pubmed: 32330343
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
Autoimmun Rev. 2020 Jul;19(7):102575
pubmed: 32376395
N Engl J Med. 2020 Jul 23;383(4):334-346
pubmed: 32598831
Kidney Int. 2020 Jun;97(6):1076-1082
pubmed: 32354637
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
J Am Soc Nephrol. 2020 Jun;31(6):1150-1156
pubmed: 32317402
Am J Transplant. 2020 Nov;20(11):3019-3029
pubmed: 32627319
Arch Dis Child. 2021 Mar;106(3):e14
pubmed: 32616522
Clin J Am Soc Nephrol. 2020 Oct 7;15(10):1494-1495
pubmed: 32718953
J Pediatric Infect Dis Soc. 2020 Nov 10;9(5):551-563
pubmed: 32750142
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
BMJ. 2020 Apr 28;369:m1669
pubmed: 32345583